At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 61 enrolled
Drug / intervention
efavirenzdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial to Assess the Efficacy of Efavirenz in Metastatic Patients With Androgen-independent Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating efavirenz for Prostate Cancer. Completed, enrolled 61 participants across 1 site.
Detailed Summary
RATIONALE: Efavirenz may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well efavirenz works in treating patients with metastatic prostate cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesFrance
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMay 2008
First PostedAug 2009
Primary CompletionSep 2011
Study CompletionApr 2014
TodayJul 2026
First PostedAug 24, 2009
Enrollment StartMay 1, 2008
Primary CompletionSep 19, 2011
Study CompletionApr 8, 2014
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 16.9 years ago
Interventions
efavirenzdrug